Supporting Information

Synergistic Inhibition of SARS-CoV-2 Replication using Disulfiram/Ebselen and Remdesivir

Ting Chen[1], Cheng-Yin Fei[2], Yi-Ping Chen[2], Karen Sargsyan[1], Chun-Ping Chang[3], Hanna S. Yuan[2]*, and Carmay Lim[1,4]*

[1]*Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan*

[2]*Institute of Molecular Biology, Academia Sinica, Taipei 115, Taiwan*

[3]*Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli 350, Taiwan*

[4]*Department of Chemistry, National Tsing Hua University, Hsinchu 300, Taiwan*

Corresponding author's e-mail: carmay@gate.sinica.edu.tw or hanna@sinica.edu.tw



Supplementary Figure S1. **Synergistic antiviral potential of disulfiram and remdesivir.** (A) A low-dosing window of synergistic antiviral effect in Vero E6 cells treated with remdesivir and disulfiram was determined. The fluorescent signal was quantified by high-content imaging analysis system (Molecular Devices) and the infection rate of no compound treatment was set as 100%. To detect SARS-CoV-2, the cells were stained with anti-SARS-CoV-2 N protein antibody and anti-human IgG-488 (shown in green). (B) The corresponding dose-based synergy scores of remdesivir and disulfiram was plotted by SynergyFinder.



Supplementary Figure S2. **Synergistic antiviral potential of ebselen and remdesivir.** (A) A low-dosing window of synergistic antiviral effect in Vero E6 cells treated with remdesivir and ebselen was determined. The fluorescent signal was quantified by high-content imaging analysis system (Molecular Devices) and the infection rate of no compound treatment was set as 100%. To detect SARS-CoV-2, the cells were stained with anti-SARS-CoV-2 N protein antibody and anti-human IgG-488 (shown in green). (B) The corresponding dose-based synergy scores of remdesivir and ebselen was plotted by SynergyFinder.